

The Small Molecule, Genistein, Increases Heparin Expression in Human Hepatocytes

Aileen W. Zhen,¹ Nancy H. Nguyen,¹ Yann Gibert,² Shmulik Motola,³ Peter Buckett,⁴
Marianne Wessling-Resnick,⁴ Ernest Fraenkel,³ and Paula G. Fraenkel¹

Heparin, a peptide hormone that decreases intestinal iron absorption and macrophage iron release, is a potential drug target for patients with iron overload syndromes because its levels are inappropriately low in these individuals. Endogenous stimulants of *Heparin* transcription include bone morphogenic protein 6 (BMP6) and interleukin-6 (IL-6) by effects on mothers against decapentaplegic homolog (Smad)⁴ or signal transducer and activator of transcription (Stat)³, respectively. We conducted a small-scale chemical screen in zebrafish embryos to identify small molecules that modulate *heparin* expression. We found that treatment with the isoflavone, genistein, from 28-52 hours postfertilization in zebrafish embryos enhanced *Heparin* transcript levels, as assessed by whole-mount *in situ* hybridization and quantitative real-time reverse-transcriptase polymerase chain reaction. Genistein's stimulatory effect was conserved in human hepatocytes: Genistein treatment of HepG2 cells increased both *Heparin* transcript levels and promoter activity. We found that genistein's effect on *Heparin* expression did not depend on estrogen receptor signaling or increased cellular iron uptake, but was impaired by mutation of either BMP response elements or the Stat3-binding site in the *Heparin* promoter. RNA sequencing of transcripts from genistein-treated hepatocytes indicated that genistein up-regulated 68% of the transcripts that were up-regulated by BMP6; however, genistein raised levels of several transcripts involved in Stat3 signaling that were not up-regulated by BMP6. Chromatin immunoprecipitation and ELISA experiments revealed that genistein enhanced Stat3 binding to the *Heparin* promoter and increased phosphorylation of Stat3 in HepG2 cells. **Conclusion:** Genistein is the first small-molecule experimental drug that stimulates *Heparin* expression *in vivo* and *in vitro*. These experiments demonstrate the feasibility of identifying and characterizing small molecules that increase *Heparin* expression. Genistein and other candidate molecules may subsequently be developed into new therapies for iron overload syndromes. (HEPATOLOGY 2013;58:1315-1325)

Heparin is a transcriptionally regulated peptide hormone¹ that is expressed primarily in the liver and excreted in urine. It is up-regulated in response to inflammation^{2,3} or iron overload⁴ and down-regulated in response to increased erythropoiesis, iron deficiency, or hypoxia.² Heparin decreases intestinal iron absorption and macrophage iron release by causing

internalization of the iron exporter, ferroportin1.⁵⁻⁷ Patients with hereditary hemochromatosis⁸ or thalassemia⁹⁻¹¹ exhibit inappropriately low levels of heparin and increased intestinal iron absorption, despite the presence of systemic iron overload.¹² Although treatment for iron overload is currently based on removal of blood or administration of iron chelators, it may be possible to

Abbreviations: Abs, antibodies; BMP, bone morphogenic protein; BRE, BMP response element; cDNA, complementary DNA; ChIP, chromatin immunoprecipitation; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; FKPM, fragments per kilobase of exon per million fragments mapped; GO, Gene Ontology; hpf, hours postfertilization; Ig, immunoglobulin; IL-6, interleukin-6; IRF9, interferon regulatory factor 9 gene; kb, kilobase; KEGG, Kyoto Encyclopedia of Genes and Genomes; MEM, minimal essential media; mRNA, messenger RNA; pRL-CMV, Renilla luciferase under control of the cytomegalovirus promoter; pStat3, phospho-Stat3; RNA-seq, RNA sequencing; RT-PCR, reverse-transcriptase polymerase chain reaction; Smad, mothers against decapentaplegic homolog; SOCS3, suppressor of cytokine signaling 3 gene; Stat3, signal transducer and activator of transcription; TGF- β , transforming growth factor beta; VEGFa, vascular endothelial growth factor A gene; WT, wild type.

From the ¹Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA; ²Metabolic Research Unit, Deakin School of Medicine, Geelong, Victoria, Australia; ³Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA; and ⁴Department of Genetics and Complex Diseases and Department of Nutrition, Harvard School of Public Health, Boston, MA.

Received August 10, 2012; accepted April 17, 2013.

prevent iron overload in patients with genetic predisposition if nontoxic small molecules can be administered that increase transcription of *Hepcidin*.

Iron overload⁴ and inflammation^{2,3} stimulate *hepcidin* expression by triggering the mothers against decapentaplegic homolog (*Smad*)-signaling or signal transducer and activator of transcription (*Stat*)-signaling pathways, respectively. It has been demonstrated that exposing human hepatocytes to bone morphogenic proteins (BMPs) up-regulates *Hepcidin* transcription by increasing Smad4 binding at Smad4-binding motifs, termed BMP response elements (BREs), in the *Hepcidin* promoter.¹³⁻¹⁶ BMPs are members of the transforming growth factor beta (TGF- β) family that signal by binding to transmembrane receptor complexes with serine-threonine kinase activity.¹⁷ Recent studies in mouse models¹⁸⁻²¹ indicate that BMP6 is the most likely physiologic regulator of *hepcidin* transcription in response to iron loading. Inflammatory stimuli, on the other hand, trigger increased serum interleukin-6 (IL-6) levels.²² IL-6 stimulates *Hepcidin* expression²³ through increased Stat3 binding to a Stat3-responsive element in the *Hepcidin* promoter.²⁴⁻²⁷

We have developed the zebrafish embryo (*Danio rerio*) as an *in vivo* model to study *hepcidin* expression. *Hepcidin* expression begins at 36 hours postfertilization (hpf) in the zebrafish embryo and is responsive to iron levels and BMPs during embryonic development.²⁸ To demonstrate that zebrafish embryos can be used to identify small-molecule modulators of *Hepcidin* expression, we screened a small number of naturally occurring isoflavones and related molecules for their effect on *Hepcidin* expression. We chose to evaluate isoflavones because they are nontoxic and are known to have kinase inhibitory actions.²⁹ In this way, we identified genistein as the first small-molecule experimental drug to increase *Hepcidin* expression *in vivo*. We found that genistein also increased *Hepcidin* expression in cultured human hepatocytes (HepG2 cells). Using

luciferase reporter assays, RNA sequencing (RNA-seq), and chromatin immunoprecipitation (ChIP), we demonstrated that genistein increases *Hepcidin* expression in a Smad4-dependent and Stat3-dependent manner.

Materials and Methods

Zebrafish Embryo Chemical Treatment, In Situ Hybridization, and Complementary DNA Preparation. Ethical approval was obtained from the institutional animal care and use committee of Beth Israel Deaconess Medical Center (Animal Welfare Assurance #A3153-01; Boston, MA) in accord with national and international guidelines. Zebrafish were maintained as previously described.³⁰ Pools of 20 embryos were treated either with 7 μ M of genistein, genistin, apigenin, daizidein, or estradiol and/or 40 μ M of dorsomorphin (all obtained from Sigma-Aldrich, St. Louis, MO) or vehicle alone (1% dimethyl sulfoxide; DMSO) from 28 to 52 hpf. Embryos were then fixed in 4% paraformaldehyde in phosphate-buffered saline for whole-mount *in situ* hybridization using anti-sense zebrafish *hepcidin* or *FOXA3* probes, as previously described.³¹ O-dianisidine staining for hemoglobin and flow cytometry were performed as described in the Supporting Materials. Representative embryos were photographed at 100 \times magnification with a BX51 compound microscope (Olympus, Center Valley, PA) and a Q-capture 5 digital camera (QImaging, Surrey, British Columbia, Canada). Expression analysis was conducted at the specified time points, by anesthetizing pools of 20 embryos with tricaine, followed by storage in RNAlater (Ambion, Life Technologies, Grand Island, NY). RNA extraction and generation of complementary DNA (cDNA) were performed as previously described.^{6,32}

Cell Culture and Chemical Treatment. The human hepatocarcinoma cell line, HepG2 (American Type Culture Collection, Manassas, VA), was maintained in alpha-minimum essential medium (α -MEM)/

Address reprint requests to: Paula Fraenkel, M.D., Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, SLD 423B, 330 Brookline Avenue, Boston, MA 02215. E-mail: pfraenke@bidmc.harvard.edu; fax: 866-345-0065.

© 2013 The Authors. HEPATOLOGY published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.

View this article online at wileyonlinelibrary.com.

DOI 10.1002/hep.26490

This work was supported by the National Institutes of Health (R01 DK085250-01A1 and 3P30 DK034 854-24S1; to P.G.F.), the Cooley's Anemia Foundation (to P.G.F.), the March of Dimes Research Foundation Basil O'Connor Starter Scholar Research Award (to P.G.F.), Harvard College Research Program (to N.N.), and the Institute for Collaborative Biotechnologies Grant W9111NF-09-001 from the U.S. Army Research Office (to S.M. and E.F.). The content of the information does not necessarily reflect the position or policy of the government, and no official endorsement should be inferred.

Potential conflict of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.

Table 1. KEGG Pathway Analysis of Genes That Were Up-Regulated by Genistein

Term	Count	P Value	Genes	Benjamini-Hochberg Statistic
hsa03010/ribosome	37	0.00E-01	RPL18, RPL13, RPS3AP47, RPL35, RPLP2, RPL36, RPL37, RPS19P3, RPL38, RPLP0P2, RPS27, RPL32, RPS11P5, RPLP1, RPL3, RPL29P26, RPL12, RPL7A, RPL10A, RPS20, RPS21, RPS13P2, RPS23, RPS15P5, RPSA, RPS16P10, RPS9, RPL27, RPL23A, RPSAP8, RPS3P3, RPS6, RPS5, RPL28, RPS8, RPL18A, RPL37A, UBA52	0.00E-01
hsa04110/cell cycle	36	0.00E-01	MAD1L1, FZR1, E2F4, PKMYT1, ANAPC11, SFN, PTTG1, ZBTB17, TGFB1, RBX1, MCM7, CDKN2B, TFPD2, MYC, CCNA2, BUB3, CUL1, ANAPC2, CREBBP, CDC20, CDK7, CDC25C, MCM5, CDC25B, CCNB1, CDKN1A, CCND1, CDKN1B, YWHAH, CCNB2, PLK1, ANAPC7, ABL1, MAD2L2, GADD45B, GADD45A	0.018
hsa03040/spliceosome	36	0.00E-01	HNRNPA1L2, CHERP, CCDC12, NHP2L1, U2AF2, LSM7, SF3B5, BUD31, XAB2, SART1, CTNBL1, SFRS4, DHX38, PRPF8, PCBP1, SFRS9, PQBP1, SNRNP70, ACIN1, LSM2, PRPF40B, DDX42, DHX8, SNRPA1, EFTUD2, SF3A2, SF3A1, EIF4A3, PIE, SNRNP200, SNRNPB, SNRPA, THOC4, PHF5A, PUF60, SNRPG	0.014
hsa05221/acute myeloid leukemia	21	0.00E-01	HRAS, PPAR, MAP2K1, MAP2K2, RELA, STAT5B, PIK3CD, PIM1, RPS6KB2, BAD, TCF7L2, STAT3, JUP, EIF4EBP1, CCND1, ARAF, IKBKG, RARA, RUNX1, MYC, AKT2	0.011
hsa04142/lysosome	33	0.01E-01	SGSH, AP1M1, CLTB, AP1B1, LGMN, HEXA, HEXB, ATP6V0B, CTS1, ATP6V0C, CD68, MAN2B1, ATP6V0D1, PSAP, ATP6V1H, AP4M1, CD63, AP4S1, CD164, LAMP1, NPC1, GLA, IGF2R, GAA, ATP6V0A1, CTSD, NEU1, CTSC, CTSB, GGA1, GGA2, CTS, GGA3	0.021
hsa05220/chronic myeloid leukemia	23	0.00153	HRAS, CTBP1, BCR, MAP2K1, MAP2K2, RELA, STAT5B, PIK3CD, BCL2L1, BAD, TGFB1, CCND1, CDKN1A, CDKN1B, GAB2, ARAF, IKBKG, SHC1, ABL1, RUNX1, SHC2, MYC, AKT2	0.046

10% certified endotoxin-free fetal bovine serum (FBS)/1% penicillin-streptomycin (Life Technologies) at 37°C in 5% CO₂. HepG2 cells were seeded onto 12-well tissue-culture-treated plates at a density of 4 × 10⁵ cells per well. Twenty-four hours later, the culture medium was changed to low-serum medium (α -MEM/1% FBS). After 8 hours of equilibration, cells were then treated for the specified time periods with genistein, genistin, apigenin, daizdein, dorsomorphin (each at 10 μ M), estradiol (0.001-100 μ M), ICI 182,780 (100 μ M) (all from Sigma-Aldrich), IL-6 20 or 100 ng/mL, BMP6 50 ng/mL (both from R&D Systems, Minneapolis, MN), or vehicle only (1% DMSO). All the samples included 1% DMSO to control for any potential effects of the vehicle.

Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction. After 18 or 24 hours of treatment, cells were harvested for extraction of total RNA using the RNeasy Mini Kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. DNA was eliminated by on-column RNase-free DNase treatment. Reverse transcription was performed using RNA (300 ng), oligo-dT, and Superscript II reverse transcriptase (RT; Life Technologies) in a 20- μ L reaction, which was later diluted to 100 μ L.

Ten percent of each RT reaction was used for a single 50- μ L quantitative real-time RT-PCR (polymerase chain reaction) assay using Taqman Universal PCR Master Mix or SYBR Green PCR Master Mix (both from Life Technologies). Primer and probe sequences are given in Supporting Table 1. Transcript levels were calculated as fold increases over the control sample. The described

reactions failed to amplify the nontemplate controls or RNA samples that were not treated with RT.

Transferrin and Nontransferrin-Bound ⁵⁵Fe Uptake Assays and Ferritin Enzyme-Linked Immunosorbent Assay. Methods for transferrin and nontransferrin-bound ⁵⁵Fe uptake assays and ferritin enzyme-linked immunosorbent assay (ELISA) are provided in the Supporting Materials.

Dual Luciferase Assay. HepG2 cells were transfected with pGL4.17 Hepc, 3 kilobases (kb) of the human *Hepcidin* promoter upstream of the firefly luciferase reporter gene, or mutated versions of the construct with point mutations in the Stat3-binding site, the BREs, or both the BRE-binding and the Stat3-binding site.³³ Additional details are provided in the Supporting Materials. The *Hepcidin* reporter constructs were donated by Drs. Ganz and Nemeth (Division of Pulmonary and Critical Care, University of California, Los Angeles). As a control, HepG2 cells were cotransfected with Renilla luciferase under control of the cytomegalovirus promoter (pRL-CMV; Promega, Madison, WI). Transiently transfected cells were treated for 6 hours with genistein (10 μ M), BMP6 (50 ng/mL), or vehicle (1% DMSO) only. The Dual-Glo Luciferase Assay (Promega) was then performed according to the manufacturer's instructions.

Statistical Analysis for Quantitative PCR, Iron Uptake, Luciferase, ChIP, and ELISA. All data shown are means \pm standard error from the mean. Data analysis was performed using Prism 5.0 (GraphPad Software, Inc., La Jolla, CA). For comparisons of

two groups, two-tailed Student *t* tests were performed comparing experimental treatment to DMSO treatment. For comparisons of three or more groups, Kruskal-Wallis' test was performed on raw data or natural logs of raw data. If $P < 0.05$, pairwise comparisons were made with two-tailed Student *t* tests. Comparisons where $P < 0.05$ were deemed significant.

RNA-seq. As described above, HepG2 cells were cultured in 12-well plates, shifted to low-serum conditions, and treated with DMSO (1%), BMP6 (50 ng/mL), or genistein (10 μ M) for 18 hours. The numbers of biological replicates were 3, 2, and 3, respectively. Details are provided in the Supporting Materials. Differential expression for BMP6-treated or genistein-treated biological replicates, compared to DMSO-treated controls, was determined using the Cufflinks tool, Cuffdiff. The criteria for differential expression were as follows: a log₂ fold-change of >0.58 or <-0.58 and a *Q* value <0.05 , when compared to the control condition. We also required that the differentially expressed genes used for downstream analysis had a fragments per kilobase of exon per million fragments mapped (FPKM) >0.1 in at least one of the conditions. Enrichments in particular biological processes, pathways, and functions were calculated statistically using the DAVID annotation database.³⁴ Prism 5.0 was used to perform linear regression analysis of the correlation between the natural log of gene expression changes measured by RNA-seq and quantitative real-time RT-PCR. All RNA-seq data have been deposited in the Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo>).

ChIP Followed by Quantitative PCR. HepG2 cells were seeded on 150-mm² plates and cultured to reach a cell density of 5×10^7 cells per plate. Eight hours before treatment, cells were washed and shifted to low-serum media (α -MEM/1% FBS). Chemicals were added to achieve either 1% DMSO, 10 μ M of genistein, 50 ng/mL of BMP6, or 20 ng/mL of IL-6. After 24 hours of treatment, cells were cross-linked by adding formaldehyde to reach a final concentration of 1%. After reversal of cross-linking, cells were lysed, sonicated, and chromatin was immunoprecipitated with antibody (Ab)-coated Dynabeads Protein G (Life Technologies). Additional details are provided in Supporting Materials. The Abs used were anti-Stat3 (sc-7154) and anti-rabbit immunoglobulin (Ig)G (sc-2027) (both from Santa Cruz Biotechnology, Santa Cruz, CA). DNA was eluted from the beads and used as a template in a quantitative PCR reaction using primers (Supporting Table 1) to amplify the proximal BMP/Stat response element, located 84 nucleotides

before the *Hepcidin* start site.²⁵ The data were reported as fold increase in binding of the specific Ab over binding to nonspecific Ig.

Stat3 ELISA. Adherent HepG2 cells (2×10^4 cells per well of a 96-well plate) were incubated in serum-free α -MEM for 16 hours, followed by the addition of the following treatments: DMSO (1%); genistein (10 μ M); or IL-6 (100 ng/mL). Cells were fixed in 4% formaldehyde after 0-60 minutes of treatment. Detection of Stat3 and phospho-Stat3 (pStat3) was performed using the Stat3 Colorimetric In-Cell ELISA Kit (Thermo Fisher Scientific Pierce, Rockford, IL), according to the manufacturer's instructions.

Results

Genistein Increases hepcidin Expression in Zebrafish Embryos. Because we had previously demonstrated evolutionarily conserved aspects of *hepcidin* regulation in zebrafish embryos,²⁸ we used zebrafish embryos to evaluate naturally occurring isoflavones (genistein and daizdein), genistin (the inactive glucoside form of genistein), or a flavone (apigenin) as potential modulators of mammalian *Hepcidin* expression. Because genistein, daizdein, and apigenin have estrogenic effects, we also evaluated estradiol. Embryos were treated from 28 to 52 hpf with the chemicals, each at 7 μ M, followed by fixation for whole-mount *in situ* hybridization (Fig. 1A) or quantitative real-time RT-PCR (Fig. 1B) to assess *hepcidin* RNA levels. We found that genistein treatment was associated with increased intensity of *hepcidin* expression (Fig. 1A,B) and an expanded domain of expression extending from the liver into the proximal intestine in 100% of 36 embryos, whereas treatment with apigenin, daizdein, estradiol, or genistin did not increase either intensity or extent of expression. However, treatment with the BMP receptor antagonist, dorsomorphin, abrogated genistein's effect on *hepcidin* expression (Fig. 1A).

The genistein-induced increase in *hepcidin* transcript levels was modest (Fig. 1B), related to decreased liver size and only a slight increase in hepatocyte-specific *hepcidin* expression (Supporting Figs. 1-3). This may explain why, despite the increase in *hepcidin* expression, staining for hemoglobin (Supporting Fig. 4) did not reveal anemia in any of the genistein-treated embryos ($n = 50$).

Genistein Increases Hepcidin Expression in HepG2 Cells. To evaluate whether genistein exerted a conserved effect on human hepatocytes, we tested the compounds in human hepatoma (HepG2) cells. We found that genistein produced a five-fold increase in




Fig. 1. Effect of genistein treatment on *Hepcidin* expression. (A and B) Zebrafish embryos were treated from 28 to 52 hpf with either estradiol (E2), genistein, apigenin, daizdein, or genistein, each at 7 μ M, and/or dorsomorphin (40 μ M), followed by fixation for whole-mount *in situ* hybridization (A) or quantitative real-time RT-PCR (B) to assess *hepcidin* RNA levels. *Hepcidin* expression was consistently increased in intensity and extent in the genistein-treated embryos, compared to DMSO-treated controls, but this effect was abrogated by cotreatment with dorsomorphin (N = 36 per group). Arrowheads mark the liver and arrows mark the proximal intestine. Scale bar = 100 microns. For quantitative real-time RT-PCR, data shown are means \pm standard error. N = 3 samples per group. * P < 0.05, compared to DMSO alone. (C-E) *Hepcidin* expression measured by quantitative real-time RT-PCR in human hepatoma (HepG2) cells after treatment with a variety of chemicals at 10 μ M (C), with genistein from 0 to 20 μ M (D), or (E) estradiol (E2) from 0 to 100 μ M in the presence or absence of the estrogen antagonist, ICI 182,780 (ICI; 100 μ M). N = 2-4 samples per condition. * P < 0.05, compared to DMSO treated. (F) Treatment with genistein for 24 hours failed to increase nontransferrin-bound iron (NTBI) uptake or transferrin-bound iron (TBI) uptake, as measured by ^{55}Fe content per microgram of protein extracted from HepG2 cells. N = 2 per group. * P < 0.05, compared to DMSO treated.

Hepcidin expression, as measured by quantitative real-time RT-PCR (Fig. 1C) that was not reproduced by treatment with the other small molecules. The effect was dose dependent (Fig. 1D), with higher increases in *Hepcidin* expression noted at 20 than 10 μ M. In

contrast, no significant increase in *Hepcidin* expression was noted after treatment with estradiol at a broad range of concentrations, ranging from 0.001 to 100 μ M (Fig. 1E). The addition of the potent estrogen receptor antagonist, ICI 182,780 (Fig. 1E), failed to

inhibit genistein's positive effects on *Hepcidin* transcript levels. In fact, the addition of the estrogen-receptor inhibitor, ICI 182,780, actually increased *Hepcidin* expression (Fig. 1E), suggesting that inhibition of estrogen receptor signaling may enhance *Hepcidin* transcript levels.

Genistein Does Not Increase Hepatocyte Iron Uptake. We considered the possibility that genistein may increase *Hepcidin* expression by promoting cellular iron loading. To evaluate this hypothesis, we tested the effect of genistein on ^{55}Fe uptake in HepG2 cells. After 24 hours of treatment with genistein, transferrin-bound iron uptake was significantly reduced, compared to vehicle alone (37.27 ± 6.29 versus 67.21 ± 2.755 ; $P < 0.05$), whereas nontransferrin-bound iron uptake was not significantly changed from vehicle-treated controls (Fig. 1F). To evaluate effects on hepatocyte iron stores (Supporting Fig. 5), we measured cellular ferritin levels after 24 hours of treatment with genistein or DMSO. We found no significant difference in ferritin levels (0.171 ± 0.058 versus 0.165 ± 0.026 ; $P = 0.92$), suggesting that the genistein-induced decrease in transferrin-bound iron uptake is offset by a hepcidin-induced decrease in ferroportin-dependent iron export.

Genistein Increases Hepcidin Promoter Activity. Because genistein did not appear to cause increased *Hepcidin* expression by enhancing cellular iron uptake, we theorized that it could enhance the effect of either of the major transcription factor pathways that have been implicated in *Hepcidin*'s regulation: Smad4 or Stat3 signaling. To interrogate these pathways, we transfected HepG2 cells with reporter constructs encoding 3 kb of the human *Hepcidin* promoter upstream of the firefly luciferase reporter gene. The promoter sequence was either wild type (WT), mutated in the Stat3-binding site, mutated in the Smad4-binding BREs, or mutated in both the Stat3-binding motif and the BREs.³³ We found that treatment with either genistein or BMP6 for 6 hours enhanced *Hepcidin*-luciferase activity by two-fold and three-fold, respectively (Fig. 2A). Mutation of the Smad4-binding BREs, with or without mutation of the Stat3 motif, decreased *Hepcidin* promoter activity below basal levels in all conditions. However, mutation of the Stat3 motif significantly impaired induction of *Hepcidin* promoter activity in the genistein-treated, but not the BMP6-treated or vehicle-treated, cells. Thus, the genistein-induced increase in *Hepcidin* promoter activity required Stat3 as well as Smad4 binding.

Inhibition of Type I BMP Receptor Activity Decreases Genistein's Effect on Hepcidin Expression. Dorsomorphin is a specific inhibitor of type I BMP receptors that has previously been shown to

impair *Hepcidin* expression.³⁵ Although treatment with dorsomorphin alone greatly reduces *Hepcidin* expression, as measured by quantitative real-time RT-PCR in HepG2 cells, cotreatment with genistein and dorsomorphin allows the *Hepcidin* transcript level to remain significantly above the basal level of expression (1.8 ± 0.15 versus 0.99 ± 0.39 ; $P < 0.05$; Fig. 2B). These observations imply that genistein activates both BMP-dependent and BMP-independent pathways.

Genistein Treatment Is Associated With Increased Transcript Levels of Many Genes That Are Up-Regulated by BMP6. To compare the effects of genistein and BMP6 on transcription in HepG2 cells, we performed high-throughput RNA-seq and identified the transcripts up-regulated in HepG2 cells after treatment with genistein ($10 \mu\text{M}$) or BMP6 (50 ng/mL) for 24 hours, in comparison to treatment with vehicle alone. We found that genistein treatment significantly up-regulated 2613 messenger RNA (mRNA) transcripts, whereas BMP6 treatment significantly increased expression of 974 RNA transcripts. Using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, we identified genistein-induced increases in transcripts of genes affecting the ribosome, cell cycle, spliceosome, acute and chronic myeloid leukemia, and the lysosome (Table 1). Among the genes in the leukemic pathway were the transcription factors, *Stat3* and *TGF β 1*, which are known to affect *Hepcidin* expression.^{24-27,36} KEGG pathways that were down-regulated after genistein treatment (Supporting Table 2) included those affecting valine, leucine, and isoleucine catabolism, fatty acid metabolism, steroid biosynthesis, and the peroxisome proliferator-activating receptor-signaling pathway.

We found that approximately two thirds of the transcripts that were up-regulated by BMP6 were also up-regulated by genistein, as illustrated in a Venn diagram (Fig. 2C) and heat map (Fig. 2D). Gene Ontology (GO) classification using the DAVID algorithm indicated that genistein and BMP6 both affect 48 fundamental cellular processes (Supporting Table 3), including translation and stress response, whereas KEGG pathway analysis demonstrated that both genistein and BMP6 increase transcript levels of ribosomal proteins (Supporting Table 4).

To validate the results of the RNA-seq analysis, we performed quantitative real-time RT-PCR to detect changes in transcript levels in genes that exhibited increased expression on RNA-seq after genistein treatment (Fig. 3A-E). We found a significant correlation between the natural log of the fold change in gene expression, as measured by quantitative PCR and RNA-seq ($R^2 = 0.7964$; Fig. 3A). Genistein




Fig. 2. Effect of genistein and BMP6 on *Hepcidin* promoter activity and transcriptional profile. (A) *Hepcidin* promoter luciferase assay. HepG2 cells were cotransfected with a Renilla control vector (pRL-CMV) and either a construct containing a 3-kb WT human *Hepcidin* promoter upstream of a firefly luciferase reporter (pink) or the same construct with inactivating mutations in the *Stat3*-binding site (orange), in the BMP response elements (light green), or in both the *Stat3*-binding site and the BMP response elements (dark green). One day after transfection, cells were treated for 6 hours with vehicle (1% DMSO), genistein (10 μ M), or BMP6 (50 ng/mL), followed by lysis and measurement of luciferase activity. *Hepcidin* promoter activity was reported as the ratio of firefly to Renilla activity and normalized to the WT *Hepcidin* promoter activity in the presence of vehicle only. Data shown are means \pm standard error. N = 4 samples per group. (B) The BMP receptor antagonist, dorsomorphin, significantly reduces genistein's effect on *Hepcidin* expression, as measured by quantitative real-time RT-PCR in HepG2 cells treated for 18 hours with vehicle (1% DMSO), dorsomorphin (10 μ M), genistein (10 μ M), or genistein and dorsomorphin combined (10 μ M of each). N = 3 samples per group. * P < 0.05, compared to DMSO treated. (C) Venn diagram illustrating results of RNA-seq. Nine hundred and seventy-four transcripts were up-regulated in HepG2 cells after treatment with BMP6 (50 ng/mL), and 2,613 transcripts were up-regulated by genistein (10 μ M), compared to treatment with 1% DMSO. Of the genes up-regulated by BMP6, 662 were also up-regulated after treatment with genistein (10 μ M), corresponding to 48 GO groups. All treatments were performed for 18 hours before harvesting cells for RNA extraction. The numbers of biological replicates were 3 (DMSO), 3 (genistein), and 2 (BMP6). (D) Heat maps displaying average fold-change in gene expression, relative to DMSO-treated cells, in the RNA-seq experiment after treatment with BMP6 (top) or genistein (bottom). In each heat map, genes were ordered from lowest to highest intensity of expression in BMP6-treated cells. Green corresponds to ≤ 0.125 fold-change, whereas red corresponds to ≥ 8 -fold change in expression over DMSO-treated controls. Gene expression was quantified as FKPM using the Cufflinks algorithm.

significantly increased transcript levels of *Stat3* and the *TGF β 1*-responsive^{37,38} gene, *Serpine1*, also known as plasminogen activator inhibitor type 1. In contrast, BMP6 treatment did not induce expression of either *Stat3* or *Serpine1* (Fig. 3B,C). Genistein treatment produced significant increases in the BMP-regulated^{17,39,40} transcripts, *Id1* and *Id3* (1.68 ± 0.11 [$P = 0.009$] and 2.11 ± 0.21 [$P = 0.01$], respectively), but these increases (Fig. 3D,E) were far lower than the increases produced by BMP6 (8.4 ± 0.44 [$P < 0.001$] and 15.3 ± 1.49 [$P < 0.001$], respectively). As expected, the BMP receptor antagonist, dorsomorphin, repressed transcript levels of *Id1* and *Id3*.

To evaluate genistein's effect on the *Stat3*-signaling pathway, in comparison to IL-6 and BMP6, we used

quantitative real-time RT-PCR to assess changes in gene expression of *Stat3*-related genes that were up-regulated by genistein on RNA-seq (Fig. 4A-E). Genistein, BMP6, or IL-6 each produced significantly increased transcript levels of *Hepcidin*; however, only genistein and IL-6 increased transcript levels of the *Stat3* target genes, suppressor of cytokine signaling 3 (*SOCS3*) and vascular endothelial growth factor A (*VEGFa*), the *Stat2*-interacting protein, interferon regulatory factor 9 gene (*IRF9*), and *IL6 receptor alpha*. In addition, genistein and IL-6 each up-regulated *TGF β 1* (Fig. 4F).

Genistein Increases *Stat3* Binding to the *Hepcidin* Promoter. Because genistein up-regulated several *Stat*-related genes and mutation of the *Stat3*-binding




Fig. 3. Validation of RNA-seq data by quantitative real-time RT-PCR. (A) Graph of correlation between the natural log of the fold-change in gene expression after genistein treatment for RNA-seq versus quantitative real-time RT-PCR analysis. Linear regression to determine the best-fit line and Pearson's coefficient R was performed using GraphPad 5.0 (GraphPad Software, Inc., La Jolla, CA). Yellow error bars include the 95% confidence interval from the best-fit line. (B-E) Quantitative real-time RT-PCR to measure the change in expression of genes that were up-regulated on RNA-seq analysis after treatment with genistein, including (B) *Stat3*, (C) *Serpine1*, (D) *Id1*, and (E) *Id3*. $N = 3$ per group. * $P < 0.05$, compared to DMSO treated.

site in the *Hepcidin* promoter impaired genistein's effect on *Hepcidin* promoter activity, we hypothesized that genistein would increase Stat3 binding to the *Hepcidin* promoter. We performed immunoprecipitation with a Stat3-specific Ab or with nonspecific IgG, followed by quantitative RT-PCR, to amplify the Stat3-binding site. We found that genistein significantly increased Stat3 binding to the *Hepcidin* promoter (9.2 ± 3.16 versus 0.94 ± 0.11 ; $P = 0.004$), whereas BMP6 did not (Fig. 5A).

Genistein Increases Stat3 Phosphorylation. To assess the effect of genistein on Stat3 activation in human hepatocytes, we treated HepG2 cells with genistein or IL-6 and assessed the ratio of pStat3 to Stat3 protein from 0 to 60 minutes after the start of treatment (Fig. 5B). We found that genistein significantly increased pStat3/Stat3 over the vehicle control after 60 minutes of treatment (3.65 ± 0.95 versus 1.03 ± 0.21 ; $p = 0.02$). As expected, IL-6 also significantly increased pStat3/Stat3 (2.81 ± 0.56 versus

1.00 ± 0.24 ; $P = 0.01$), but the effect peaked after 30 minutes of treatment.

Discussion

In our study, we identified genistein as the first small-molecule experimental drug to up-regulate *Hepcidin* transcript levels *in vivo* and *in vitro*. Genistein is known to cause both estrogen receptor-dependent and receptor-independent effects. Genistein exhibits estrogenic effects on gene transcription,⁴¹⁻⁴³ scavenges free radicals,⁴⁴ and inhibits numerous protein tyrosine kinases.²⁹ We found that genistein's effect on *Hepcidin* expression was estrogen receptor independent. Estradiol failed to increase *Hepcidin* expression in either zebrafish embryos or HepG2 cells, and the potent estrogen receptor inhibitor, ICI 182,780, failed to block genistein's effect. In fact, we found that ICI 182,780 stimulated *Hepcidin* expression. These observations agree with recently published data indicating that




Fig. 4. Effect of genistein on Stat3-related genes and TGF- β 1 in HepG2 cells. (A-F) Quantitative real-time RT-PCR comparing changes in mRNA expression in HepG2 cells after treatment for 24 hours with genistein (10 μ M), BMP6 (50 ng/mL), or IL-6 (100 ng/mL) in (A) *Hepcidin*, (B) *SOCS3*, (C) *IRF9*, (D) *VEGFA*, (E) *IL6 receptor*, and (F) *TGF β 1*. N = 2-6 per group. * $P < 0.05$, compared to DMSO treated.

estradiol does not increase *Hepcidin* expression, and that ICI 182,780 increases *Hepcidin* transcript levels in HepG2 cells in the presence or absence of estradiol.⁴⁵

Hepcidin exerts control over iron homeostasis by decreasing intestinal iron absorption and macrophage iron release in response to excessive accumulation of iron in vital organs. Hepatic iron overload increases *hepcidin* transcript levels in normal mice⁴⁶ and humans.⁴⁶ Thus, we hypothesized that genistein might increase *Hepcidin* expression by enhancing hepatocyte iron uptake. We found that genistein failed to increase either transferrin-bound or nontransferrin-bound iron uptake. Thus, genistein does not appear to increase cellular iron overload, which is encouraging in a potential therapy for hemochromatosis.

Our *in vivo* zebrafish and human hepatocyte data (Figs. 1 and 2) indicate that BMP signaling is required for *hepcidin* expression, and that genistein's effect on *hepcidin* expression is diminished by the BMP antagonist, dorsomorphin. Although our RNA-seq data indicate that genistein up-regulated 68% of the genes that

were up-regulated by BMP6, genistein's mode of action differed from BMP6's. Genistein increased *Hepcidin* promoter activity in a Stat3-dependent manner, whereas BMP6 did not. We also identified several genes in the Janus kinase/Stat-signaling pathway that were up-regulated by genistein, but not by BMP6. For example, *Stat3* itself, *IL6 receptor*, *SOCS3*, *Serpine1*, and *VEGFA*, all of which are up-regulated in response to Stat3 activation,⁴⁷ and *IRF9*, which interacts with Stat2 (reviewed elsewhere⁴⁸). Increasing *IL6 receptor* expression would be expected to increase sensitivity to IL6, which, in turn, could promote *Hepcidin* expression. Genistein also increased the expression of TGF- β 1, a Smad4-signaling protein that has been shown to increase *Hepcidin* expression.³⁶

Previously, genistein has been reported either to promote or inhibit Stat3 phosphorylation. This apparently paradoxical effect appears to be dose dependent. At lower concentrations, such as those used in our study, genistein promotes Stat3 phosphorylation and cell proliferation,⁴⁹ whereas at high concentrations (40-50




Fig. 5. Effect of genistein on Stat3 binding to the *Hepcidin* promoter and Stat3 phosphorylation. (A) HepG2 cells were treated for 24 hours with DMSO (1%), BMP6 (50 ng/mL), IL-6 (20 ng/mL), or genistein (10 μ M) in media containing 1% FBS, followed by ChIP with an Ab specific for Stat3 (Santa Cruz Biotechnology, Santa Cruz, CA) or with nonspecific IgG. After reversal of cross-linking, quantitative PCR with primers specific for the Stat3-binding site was performed to determine the fold change in Stat3 binding to the *Hepcidin* promoter, relative to nonspecific IgG binding. Data shown are means \pm standard error (SE). N = 3-4 samples per group. * P < 0.05, compared to DMSO treated. (B) ELISA was used to quantify the ratio of pStat3 to Stat3 protein in HepG2 cells in serum-free media after exposure to IL-6 (100 ng/mL, light green triangles) or genistein (10 μ M, orange squares), normalized to vehicle (1% DMSO, black circles) from 0 to 60 minutes. Data shown are means \pm SEs. * P < 0.05 for IL-6 versus DMSO; ** P < 0.05 for genistein versus DMSO. N = 7 per time point per group.

μ M) genistein inhibits Stat3 phosphorylation and cell proliferation^{49,50} and promotes apoptosis.⁴⁹ Consistent with these observations, we found that 10 μ M of genistein enhanced Stat3 phosphorylation and Stat3 binding to the *Hepcidin* promoter in cultured human hepatocytes.

We have demonstrated that genistein increases hepcidin expression in human hepatocytes in a Stat3-dependent and Smad4-dependent manner. The screening technique that we have developed may be used to identify other *Hepcidin* regulatory molecules with different modes of action. Genistein and other candidate molecules may subsequently be tested in preclinical models of iron overload syndromes and used to develop new therapies for iron overload.

Acknowledgment: The authors thank Eric Samarut for his assistance with the zebrafish experiments, Anthony Soltis for his assistance with the heat map, and Dr. Nancy Berliner for her critical review of the manuscript.

References

- Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. *Cell* 2004;117:285-297.
- Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by

- anemia, hypoxia, and inflammation. *J Clin Invest* 2002;110:1037-1044.
- Shike H, Shimizu C, Lauth X, Burns JC. Organization and expression analysis of the zebrafish hepcidin gene, an antimicrobial peptide gene conserved among vertebrates. *Dev Comp Immunol* 2004;28:747-754.
- Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem* 2001;276:7811-7819.
- Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004;306:2090-2093.
- Fraenkel PG, Traver D, Donovan A, Zahrieh D, Zon LI. Ferroportin1 is required for normal iron cycling in zebrafish. *J Clin Invest* 2005;115:1532-1541.
- Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell Metab* 2005;1:191-200.
- Anderson GJ, Frazer DM. Iron metabolism meets signal transduction. *Nat Genet* 2006;38:503-504.
- Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. *Blood* 2005;105:4103-4105.
- Kattamis A, Papassotiriou I, Palaiologou D, Apostolou F, Galani A, Ladis V, et al. The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. *Haematologica* 2006;91:809-812.
- Camberlein E, Zanninelli G, Detivaud L, Lizzi AR, Sorrentino F, Vacquer S, et al. Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. *Haematologica* 2008;93:111-115.
- Finch C. Regulators of iron balance in humans. *Blood* 1994;84:1697-1702.
- Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. *J Mol Med (Berl)* 2008;86:531-540.
- Island ML, Jouanolle AM, Mosser A, Deugnier Y, David V, Brissot P, Loreal O. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. *Haematologica* 2009;94:720-724.
- Casanovas G, Mleczyk-Sanecka K, Altamura S, Hentze MW, Muckenthaler MU. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. *J Mol Med (Berl)* 2009;87:471-480.
- Mleczyk-Sanecka K, Casanovas G, Ragab A, Breitkopf K, Muller A, Boutros M, et al. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. *Blood* 2010;115:2657-2665.
- Conidi A, Cazzola S, Beets K, Coddens K, Collart C, Cornelis F, et al. Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGFbeta/BMP signaling *in vivo*. *Cytokine Growth Factor Rev* 2011;22:287-300.
- Andriopoulos B, Jr., Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. *Nat Genet* 2009;41:482-487.
- Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. *Nat Genet* 2009;41:478-481.
- Arndt S, Maegdefrau U, Dorn C, Schardt K, Hellerbrand C, Bosscheroff AK. Iron-induced expression of bone morphogenetic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression *in vivo*. *Gastroenterology* 2010;138:372-382.
- Kautz L, Besson-Fournier C, Meynard D, Latour C, Roth MP, Coppin H. Iron overload induces BMP6 expression in the liver but not in the duodenum. *Haematologica* 2011;96:199-203.

22. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. *Blood* 2005;106:1864-1866.
23. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest* 2004;113:1271-1276.
24. Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, et al. C/EBP α regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. *J Biol Chem* 2002;277:41163-41170.
25. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. *Blood* 2006;108:3204-3209.
26. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. *Blood* 2007;109:353-358.
27. Matak P, Chaston TB, Chung B, Srai SK, McKie AT, Sharp PA. Activated macrophages induce hepcidin expression in HuH7 hepatoma cells. *Haematologica* 2009;94:773-780.
28. Fraenkel PG, Gibert Y, Holzheimer JL, Lattanzi VJ, Burnett SF, Doolley KA, et al. Transferrin- α modulates hepcidin expression in zebrafish embryos. *Blood* 2009;113:2843-2850.
29. Yan GR, Xiao CL, He GW, Yin XF, Chen NP, Cao Y, He QY. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. *Proteomics* 2010;10:976-986.
30. Westerfield M. *The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Brachydanio rerio)*. Eugene, OR: University of Oregon Press; 1994.
31. Gibert Y, Lattanzi VJ, Zhen AW, Vedder L, Brunet F, Faasse SA, et al. BMP signaling modulates hepcidin expression in zebrafish embryos independent of hemojuvelin. *PLoS One* 2011;6:e14553.
32. Goessling W, North TE, Lord AM, Ceol C, Lee S, Weidinger G, et al. APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. *Dev Biol* 2008;320:161-174.
33. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. *Blood* 2010;116:3635-3644.
34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44-57.
35. Yu PB, Hong CC, Sachidanandan C, Babbitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. *Nat Chem Biol* 2008;4:33-41.
36. Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. *Cell Metab* 2005;2:399-409.
37. Denler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* 1998;17:3091-3100.
38. Nakayama N, Nakamura T, Okada H, Iwaki S, Sobel BE, Fujii S. Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor- β . *Coron Artery Dis* 2011;22:468-478.
39. Lopez-Rovira T, Chalaux E, Massague J, Rosa JL, Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. *J Biol Chem* 2002;277:3176-3185.
40. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smealand EB, Rian E. BMP-6 inhibits human bone marrow B lymphopoiesis—upregulation of Id1 and Id3. *Exp Hematol* 2006;34:72-81.
41. Ise R, Han D, Takahashi Y, Terasaka S, Inoue A, Tanji M, Kiyama R. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. *FEBS Lett* 2005;579:1732-1740.
42. Satih S, Chalabi N, Rabiau N, Bosviel R, Fontana L, Bignon YJ, Bernard-Gallon DJ. Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach. *OMICS* 2010;14:231-238.
43. Jefferson WN, Couse JF, Padilla-Banks E, Korach KS, Newbold RR. Neonatal exposure to genistein induces estrogen receptor (ER) α expression and multioocyte follicles in the maturing mouse ovary: evidence for ER β -mediated and nonestrogenic actions. *Biol Reprod* 2002;67:1285-1296.
44. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. *Cancer Lett* 2008;269:226-242.
45. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17 β -estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. *Endocrinology* 2012;153:3170-3178.
46. Bolondi G, Garuti C, Corradini E, Zoller H, Vogel W, Finkenstedt A, et al. Altered hepatic BMP signaling pathway in human HFE hemochromatosis. *Blood Cells Mol Dis* 2010;45:308-312.
47. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. *Oncogene* 2005;24:3397-3408.
48. Reich NC, Liu L. Tracking STAT nuclear traffic. *Nat Rev Immunol* 2006;6:602-612.
49. Chau MN, El Touny LH, Jagadeesh S, Banerjee PP. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. *Carcinogenesis* 2007;28:2282-2290.
50. Kim EK, Kwon KB, Song MY, Seo SW, Park SJ, Ka SO, et al. Genistein protects pancreatic beta cells against cytokine-mediated toxicity. *Mol Cell Endocrinol* 2007;278:18-28.